GlassScriptPhysician profile
Trinese Hardy
NPI 1184683872
$29,569.09
in general payments reported to CMS, 2019-2025
20 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.81 · 2022: $117 · 2023: $1,181 · 2024: $11K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $7,727 · Travel and Lodging: $4,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,321.00 |
| Food and Beverage | $7,727.05 |
| Travel and Lodging | $4,390.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16,887.48 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $7,125.50 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $1,020.19 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $914.46 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $792.12 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $640.63 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $531.55 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $402.30 | 2023-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $207.18 | 2023-2025 | Ingrezza |
| Corium, LLC | $187.66 | 2023-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $174.92 | 2025 | Qelbree |
| Luye Pharma (USA) LTD. | $124.99 | 2025 | Erzofri Extended-Release |
| Idorsia Pharmaceuticals US INC | $123.97 | 2024 | Quviviq |
| Tris Pharma INC | $119.56 | 2024 | Dyanavel Xr |
| Gilead Sciences, INC. | $116.55 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $113.12 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.46 | 2024 | Caplyta |
| Indivior INC. | $22.24 | 2024 | Perseris |
| Acadia Pharmaceuticals INC | $19.64 | 2024 | Nuplazid |
| Noven Therapeutics, LLC | $18.57 | 2025 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trinese Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.